Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13278032 | 0.78 | ADRA2A (0.36) | ADRA2APARP1HTR7 | |
| SCHEMBL1265527 | 0.78 | CYP19A1 (0.46) | CYP19A1ADRA2APARP1 | |
| SCHEMBL1266361 | 0.77 | LMNA (0.40) | CYP19A1ADRA2APARP1 | |
| SCHEMBL30989926 | 0.77 | LMNA (0.40) | CYP19A1ADRA2APARP1 | |
| SCHEMBL25937578 | 0.77 | LMNA (0.40) | CYP19A1ADRA2APARP1 | |
| SCHEMBL1266362 | 0.77 | LMNA (0.40) | CYP19A1ADRA2APARP1 | |
| SCHEMBL12607167 | 0.74 | CYP19A1 (0.37) | CYP19A1ADRA2APGRPARP1 | |
| SCHEMBL20205644 | 0.74 | CYP19A1 (0.37) | CYP19A1ADRA2APGRPARP1ACHE | |
| SCHEMBL1829390 | 0.73 | CYP19A1 (0.39) | CYP19A1ADRA2APGRPARP1 | |
| SCHEMBL1994297 | 0.73 | CYP19A1 (0.39) | CYP19A1ADRA2APGRPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786823-B1 | ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2008-01-16 | — | — | EP | disclosed |
| EP-1786823-A1 | ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-05-23 | — | — | EP | disclosed |
| US-20060167025-A1 | Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs | SCHERING AG (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066950-A2 | TRICYCLIC AMINOALCOHOLS, METHODS FOR PRODUCING THE SAME AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060084652-A1 | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2006-04-20 | — | — | US | disclosed |
| WO-2006027236-A1 | ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167025-A1 | Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs | ALDH7A1, NOTUM, GOT2 | CYP19A1 1890/4885ADRA2A 1503/4885PGR 4292/4885 |
| US-20060084652-A1 | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | PTGES, PTGS1, PTGES2 | CYP19A1 406/4885ADRA2A 902/4885PGR 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.